Cadila Healthcare Swings After U.S. FDA Issues 14 Observations For Moraiya Plant
Tablets arranged for a photograph. (Photographer: Kiyoshi Ota/Bloomberg)

Cadila Healthcare Swings After U.S. FDA Issues 14 Observations For Moraiya Plant

Cadila Healthcare Ltd. said the U.S. Food and Drug Administration issued Form 483 with 14 observations after the drug regulator inspected its formulations manufacturing facility in Moraiya, Ahmedab...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.